PDEδ degradation disrupts KRAS membrane localization to collapse oncogenic signaling through spatial pharmacology rather than direct enzymatic inhibition.
Dr. Mark Nelson of Neumedics outlines how integrating medicinal chemistry with scalable API synthesis from the earliest design stages defines the next evolution of pharmaceutical development.
Dr. Joseph Stalder of Zentalis Pharmaceuticals examines how predictive data integration and disciplined program governance are redefining the future of late-stage oncology development.
Senior Director Dr. Leo Kirkovsky brings a rare cross-modality perspective—spanning physical organic chemistry, clinical assay leadership, and ADC bioanalysis—to show how ADME mastery becomes the decision engine that turns complex drug systems into scalable oncology development programs.
Global pharmaceutical access improves when IP, payment, and real-world evidence systems are engineered as interoperable feedback loops rather than isolated reforms.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settings